Please assess the completion status of the following clinical trial:

Trial Title: The Antiplatelet and Immune Response Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects, or female subjects not of childbearing potential (either surgically sterile or post menopausal)~* Age between 18 and 65 years inclusive~* Non smokers~* Body mass index (BMI) between 18 and 28 kg/m2 inclusive, with a body weight between 60-100 kg~* Subjects are to be in good health as determined by a medical history, physical examination, vital signs and clinical laboratory test results including renal and liver function and full blood count~* Subjects have given their informed consent before any trial-related activity~Exclusion Criteria:~* In the opinion of the investigator, subjects with, or a history of, cancer, diabetes or clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, haematological, dermatological, neurological, psychiatric, or other major disorders~* Subjects with a history of significant multiple drug allergies or with a known allergy to the study drugs or a medicine chemically related to the trial product~* Subjects who have had a clinically significant illness within 4 weeks of dosing~* Subjects taking regular medicines including NSAIDs, antibiotics, aspirin or anticoagulant therapy~* Any clinically significant abnormal laboratory test results at screening~* Subjects who have a supine blood pressure at screening, after resting for 5 minutes, higher than 150/90 mmHg or lower than 105/65 mmHg~* Subjects who have a supine heart rate at screening, after resting for 5 minutes, outside the range of 50-100 beats/min~* Subjects who have received any prescribed systemic or topical medication within two weeks prior to the start of dosing. Limited use of paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) prior to the initiation of the study will not necessarily require exclusion unless there is an ongoing requirement for these medications.~* Subjects who have received an investigational medicinal product within the previous four months (new chemical entity) or three months (licensed product) or subjects who have received a vaccine within three months preceding the start of dosing~* Subjects who have donated any blood or plasma in the month preceding the start of dosing~* Subjects who have a history of alcohol or drug abuse~* Subjects with mental incapacity or language barriers which preclude adequate understanding~* Subjects with a contraindication to ticagrelor (as listed in the SmPC - hypersensitivity to the active substance or any of its excipients, active pathological bleeding, history of intracranial hemorrhage, moderate to severe hepatic impairment and co-administration with strong CYP3A4 inhibitors)~* Subjects with a contraindication to clopidogrel (as listed in the SmPC - hypersensitivity to the active substance or any of its excipients, severe hepatic impairment, active pathological bleeding such as peptic ulcer or intracranial haemorrhage)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Clopidogrel & Endotoxin (Type: EXPERIMENTAL): Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily~E.coli Endotoxin Day 7 - 2 ng/kg
- No antiplatelet medication & Endotoxin (Type: PLACEBO_COMPARATOR): No antiplatelet medication~E.coli Endotoxin Day 7 - 2 ng/kg
- Ticagrelor & Endotoxin (Type: EXPERIMENTAL): Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily~E.coli Endotoxin Day 7 - 2 ng/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).